RANCHO CORDOVA, Calif. and WEST LAFAYETTE, Ind., Feb. 24, 2014 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (Nasdaq:KOOL), formerly known as ThermoGenesis Corp., announced today that they have entered a supply agreement with Cook Medical.
"We have found the ideal partner in Cook Medical to supply catheters, angioplasty balloons and other interventional products for the AMIRST Phase 1b trial," said Matthew Plavan, CEO, Cesca Therapeutics.
Under the terms of the agreement, Cook Medical has been chosen as the supplier for select delivery device products for the AMIRST (Acute Myocardial Infarction Rapid Stem cell Therapy) Phase Ib trial set to begin later this calendar year. The clinical trial is for targeted marketing approval in the United States, European Union Community and India.
Ken Harris, President of Cesca Therapeutics commented, "We look forward to Cook Medical's product contribution to the AMIRST trial, and know that their expertise in medical devices will support our success and advancing the field of regenerative and cellular medicine."
About Cesca Therapeutics
Cesca Therapeutics Inc. (www.cescatherapeutics.com) is engaged in the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine. We are also a leader in developing and manufacturing automated blood and bone marrow processing systems and companion disposable products that enable the separation, processing and preservation of cell and tissue therapy products. These include:
-- SurgWerKs™ Platform, a proprietary stem cell therapy point-of-care kit system for treating vascular and orthopedic indications that integrate the following indication specific systems:
- Cell harvesting
- Cell processing and selection
- Cell diagnostics
- Cell delivery
-- AXP® AutoXpress® Platform (AXP), a proprietary family of automated devices that includes the AXP and the MXP® MarrowXpress® and companion sterile blood processing disposables for harvesting stem cells in closed systems. The AXP device is used for the processing of cord blood.
-- The MarrowXpress Platform (MXP), a derivative product of the AXP and its accompanying disposable bag set, isolates and concentrates stem cells from bone marrow. Self-powered and microprocessor-controlled, the MXP contains flow control optical sensors that volume-reduces blood from bone marrow to a user defined volume in 30 minutes, while retaining over 90% of the MNCs.
-- The Res-Q™ 60 (Res-Q), a point-of-care system designed for the preparation of cell concentrates, including stem cells, from bone marrow aspirates and whole blood for platelet rich plasma (PRP).
-- The BioArchive® System, an automated cryogenic device, used by cord blood stem cell banks in more than 30 countries for cryopreserving and archiving cord blood stem cell units for transplant.
This press release contains forward-looking statements. Such forward-looking statements include but are not limited to that Cesca Therapeutics Inc. will provide unmatched world-class capability and service to its clients. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. A more complete description of risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in ThermoGenesis annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.
CONTACT: Cesca Therapeutics Inc. Web site: http://www.CescaTherapeutics.com Investor Relations +1-916-858-5107
Source:Cesca Therapeutics Inc.